RecruitingNCT07065240
SPT-300 for major depression, with or without anxiety symptoms
About this title
Read the official source — NCT07065240Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
Participants are randomly assigned to take SPT-300 or a matching placebo (an inactive comparison treatment) once a day for 42 days.
- Listed locations
- Chino and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 19, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 360
- Sponsor
- Seaport Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07065240
- Official title
Show the full official title
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Recruitment & locations
RecruitingChino, United States · Garden Grove, United States · Glendale, United States
51 more locations
- Redlands, United States
- San Jose, United States
- Cromwell, United States
- Jacksonville, United States
- Lauderhill, United States
- Orlando, United States
- Palm Bay, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Boston, United States
- Russells Mills, United States
- St Louis, United States
- Brooklyn, United States
- Cedarhurst, United States
- New York, United States
- Staten Island, United States
- Independence, United States
- North Canton, United States
- Allentown, United States
- Dallas, United States
- Irving, United States
- Richardson, United States
- Everett, United States
- Lovech, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Brno, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Berlin, Germany
- Schwerin, Germany
- Bad Homburg, Germany
- Chemnitz, Germany
- Budapest, Hungary
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Leszno, Poland
- Poznan, Poland
- Torun, Poland
- Tuszyn, Poland
- Warsaw, Poland
- Wroclaw, Poland
- Bratislava, Slovakia
- Rimavská Sobota, Slovakia
- Vranov nad Topľou, Slovakia
- Czechia
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing SPT-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Seaport Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including SPT-300 and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
